Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imidapril

Drug Profile

Imidapril

Alternative Names: Novarok; SH 6366; TA 6366; Tanatril

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanabe Seiyaku
  • Developer G.L. Pharma; Gerolymatos Group; Mitsubishi Tanabe Pharma Corporation; Trinity-Chiesi Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Imidazolidines; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic nephropathies

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 03 Aug 2005 Xanodyne Pharmaceuticals has acquired the pharmaceutical assets of aaiPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top